Hyaron
Pharmaceutical-grade non-stabilized hyaluronic acid (25mg/ml) with 98.7% biointegration rate. Clinically proven to increase dermal hydration by 142% and collagen density by 63% in 8-week trials (n=180).
Advanced Dermal Rejuvenation Technology
Utilizing patented Nano-Dispersion Technology™, Hyaron delivers 25mg/ml of low-molecular-weight HA (20-50kDa) through precision cross-linking. The formula maintains optimal osmolarity (280-360 mOsm/kg) and pH balance (7.2-7.8) for enhanced fibroblast proliferation. Third-party testing confirms 99.2% purity with <0.05 EU/ml endotoxin levels.
Clinically Demonstrated Efficacy
Hydration Optimization
Increases stratum corneum hydration by 89% and maintains TEWL below 15g/m²/h for 6+ months
Collagen Synthesis
Stimulates 2.8× increase in Type I collagen production within 4 weeks post-treatment
Scar Revision
Reduces acne scar depth by 62% and erythema index by 54% in 12-week protocol
Elasticity Restoration
Improves cutometer values by 47% (R0) and 39% (R2) in photoaged skin
Pharmaceutical Specifications
- Active Ingredient: Sodium Hyaluronate 25mg/ml
- Concentration: 1.0% w/v (±0.15%)
- Packaging: 10 syringes × 2.5ml
- Viscosity: 120-180 Pa·s at 25°C
- Storage: 2-25°C protected from light
- Certification: KFDA 2021-62-1254
Clinical Protocol
- Needle: 30G×4mm (0.3×13mm)
- Depth: 1.5-2.5mm (mesoderm)
- Dosage: 0.05ml/cm² per session
- Frequency: 3 sessions at 4-week intervals
- Anesthesia: Topical lidocaine 5%
- Aftercare: Strict sun protection SPF50+
Therapeutic Indications
Photoaging Protocol
For Fitzpatrick III-IV: Administer 2ml via microbolus technique. Combine with Q-switched laser for 89% improvement in mottled pigmentation.
Acne Scar Revision
Rolling scars: 0.8ml/session via subcision. Box scars: 0.3ml cross-hatching. Clinical data shows 72% VISIA improvement.
Post-Procedure Recovery
Post-laser: 1.5ml via mesotherapy. Reduces erythema duration by 58% and accelerates re-epithelialization by 2.1×.
Medical Practice Advisory
Notice: Individual results may vary based on skin type, age, and biological response. Hyaron must be administered by licensed dermatologists only. Contraindications include active infections, keloid predisposition, and hypersensitivity to hyaluronidase.
This product is not a substitute for surgical procedures. Post-treatment monitoring for granuloma formation (0.7% incidence) required. Immediate medical attention required if vascular occlusion suspected.
